EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study

L. Carril Ajuria, M. Naigeon, R. Flippot, C. Dalban, A. Desnoyer, N. Rioux-Leclercq, C. Sautes-Fridman, M. Meylan, Y. Vano, B. Beuselinck, S. Chouaib, C. de Oliveira und 4 weitere

Immuno-Oncology and Technology · 2023-12 · 20 · 100643

DOI: 10.1016/j.iotech.2023.100643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immuno-Oncology and Technology, 2023-12. Verfasst von L. Carril Ajuria und 15 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer, Merck.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy is standard of care in mRCC but tools for patients’ selection are lacking. The NIVOREN GETUG-AFU 26 study of nivolumab in mRCC included a translational program with assessment of circulating cytokines. We found IL-8 to be associated with overall survival (Carril-Ajuria et al. ASCO. 2022). Here, we aimed to evaluate the association between IL-8 and the mRCC immune landscape, including both circulating and tissue-based assessments. Out of 720 pts treated with nivo within the NIVOREN study, 353 with available cytokine quantification were included for analysis. Immunohistochemistry expression of VEGF and CD163 at the invasive margin (IM) and at the tumor core (TC) was assessed. Previously published tissue-based GS were analyzed, including IMmotion myeloid, IMmotion Teff, and JAVELIN 101 immuno. Circulating inflammatory markers included neutrophils, NLR (neutrophil lymphocyte ratio), LIPI (Lung Immune Prognostic Index, based on derived NLR>3 and LDH>upper limit of normal). The association of baseline levels of IL-8 with baseline levels of circulating inflammatory markers, and with VEGF/CD163 expression and tissue-based GS expression were analyzed. Baseline characteristics were similar to the overall trial population. Higher levels of baseline circulating IL-8 (cut-off:17.9 pg/ml) were associated with increased baseline circulating neutrophiles (p=0.046), and NLR (p=0.008) as well as with LIPI (p=0.005). Among 353 pts, only 64 had available information on GS expression. Baseline IL-8 significantly correlated with increased IMmotion myeloid expression (p=0.041). No significant correlations between baseline circulating IL-8 and the other two GS, VEGF or CD163 expression were observed. In our study, elevated baseline circulating IL-8 was not only significantly associated with higher levels of other circulating inflammatory markers, but also with increased expression of the myeloid inflammation gene signature at tumor level in mRCC pts.

Förderung

  • Pfizer
  • Merck

Zitieren

APA

Ajuria, L. C., Naigeon, M., Flippot, R., Dalban, C., Desnoyer, A., Rioux-Leclercq, N., Sautes-Fridman, C., Meylan, M., Vano, Y., Beuselinck, B., Chouaib, S., Oliveira, C. D., Tantot, F., Escudier, B., Chaput-Gras, N., & Albiges, L. (2023). 184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study. Immuno-Oncology and Technology, 20, 100643. https://doi.org/10.1016/j.iotech.2023.100643

Vancouver

Ajuria LC, Naigeon M, Flippot R, Dalban C, Desnoyer A, Rioux-Leclercq N, et al. 184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study. Immuno-Oncology and Technology. 2023;20:100643. doi:10.1016/j.iotech.2023.100643

BibTeX
@article{Ajuria2023,
  author = {Ajuria, L. Carril and Naigeon, M. and Flippot, R. and Dalban, C. and Desnoyer, A. and Rioux-Leclercq, N. and Sautes-Fridman, C. and Meylan, M. and Vano, Y. and Beuselinck, B. and Chouaib, S. and Oliveira, C. de and Tantot, F. and Escudier, B. and Chaput-Gras, N. and Albiges, L.},
  title = {184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study},
  journal = {Immuno-Oncology and Technology},
  year = {2023},
  volume = {20},
  pages = {100643},
  doi = {10.1016/j.iotech.2023.100643}
}
Kostenlos starten →